more

Halozyme Therapeutics (HALO)

(Real Time Quote from BATS)

$58.58 USD

-1.85 (-3.06%)

Updated Oct 4, 2024 03:08 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research Published on October 26,2020

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALONegative Net Change

J&J Seeks Label Expansion of Darzalex Faspro for Amyloidosis

by Zacks Equity Research Published on September 11,2020

J&J (JNJ) files sBLA to the FDA for expanding the label of Darzalex Faspro to treat patients with light chain amyloidosis. Currently, there are no approved therapies for the disease.

pharmaceuticals

Halozyme Therapeutics (HALO) Down 1.6% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research Published on September 09,2020

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HALONegative Net Change

Halozyme (HALO) Q2 Earnings and Revenues Miss Estimates

by Zacks Equity Research Published on August 11,2020

Halozyme (HALO) reports lower-than-expected Q2 earnings. Shares down.

Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Lag Estimates

by Zacks Equity Research Published on August 10,2020

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -24.00% and -20.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

HALONegative Net Change

Biotech Stock Q2 Earnings on Aug 10: NVAX, ICPT & More

by Kinjel Shah Published on August 07,2020

Let us take a look at five small biotech companies, NVAX, ICPT, FOLD, RETA, HALO, which are gearing up for their earnings release.

biotechs

Halozyme Therapeutics (HALO) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research Published on August 03,2020

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALONegative Net Change

Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?

by Zacks Equity Research Published on July 28,2020

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

HALONegative Net Change

Roche's SC Formulation of Perjeta-Herceptin Combo Gets FDA Nod

by Zacks Equity Research Published on June 30,2020

Roche (RHHBY) receives FDA approval for a fixed-dose combination of Perjeta and Herceptin, Phesgo, plus chemotherapy as a treatment for HER2-positive breast cancer.

biotechs

Why Halozyme Therapeutics (HALO) Stock Might be a Great Pick

by Zacks Equity Research Published on June 19,2020

Halozyme Therapeutics (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

HALONegative Net Change

medical

Why Is Halozyme Therapeutics (HALO) Up 1% Since Last Earnings Report?

by Zacks Equity Research Published on June 10,2020

Halozyme Therapeutics (HALO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HALONegative Net Change

J&J's Darzalex Subcutaneous Version Gets Approval in Europe

by Zacks Equity Research Published on June 05,2020

J&J (JNJ) announces approval of subcutaneous formulation of Darzalex for all current MM indications in first-line as well as relapsed/refractory multiple myeloma.

pharmaceuticals

ACADIA to Merge Two Phase III Studies on Nuplazid for MDD

by Zacks.com Published on May 27,2020

ACADIA (ACAD) to club two late-stage studies on Nuplazid into a single evaluation program for the adjunctive treatment of MDD. Top-line results from the same are expected in Q3.

biotechs

argenx Up on Positive Data from Pivotal Efgartigimod Study

by Zacks Equity Research Published on May 27,2020

argenx's (ARGX) lead pipeline candidate, efgartigimod, meets primary endpoint in a pivotal study evaluating it in myasthenia gravis. A BLA is likely to be filed by the end of 2020.

biotechs

Why Halozyme (HALO) Could Be Positioned for a Surge

by Zacks Equity Research Published on May 20,2020

Halozyme (HALO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

HALONegative Net Change

medical

Why Halozyme (HALO) Stock Might be a Great Pick

by Zacks Equity Research Published on May 19,2020

Halozyme (HALO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

HALONegative Net Change

medical

Top Ranked Momentum Stocks to Buy for May 15th

by Zacks Equity Research Published on May 15,2020

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 15th

Halozyme (HALO) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research Published on May 12,2020

Halozyme (HALO) reports wider-than-expected Q1 loss. Shares down.

Halozyme Therapeutics (HALO) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research Published on May 11,2020

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of -300.00% and -35.57%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

HALONegative Net Change

Will Halozyme Therapeutics Continue to Surge Higher?

by Zacks Equity Research Published on May 08,2020

As of late, it has definitely been a great time to be an investor Halozyme Therapeutics

HALONegative Net Change

medical

Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research Published on April 28,2020

Halozyme Therapeutics (HALO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.